FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382399821> ?p ?o ?g. }

• W4382399821 endingPage "1209" @default.
• W4382399821 startingPage "1197" @default.
• W4382399821 abstract "Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain treatment outcomes of first-line afatinib for patients with epidermal growth factor receptor (EGFR)-mutant NSCLC with BM in a real-world setting.This retrospective observational study reviewed electronic records of patients with EGFR-mutant NSCLC who received first-line afatinib treatment between October 2014 and October 2019 in 16 hospitals across South Korea. The Kaplan-Meier method estimated time on treatment (TOT) and OS; multivariate analyses were performed using Cox proportional hazards (PH) models.Among 703 patients who received first-line afatinib, 262 (37.3%) had baseline BM. Of 441 patients without baseline BM, 92 (20.9%) developed central nervous system (CNS) failure. Compared with patients without CNS failure, those with CNS failure during afatinib treatment were younger (P=0.012), had a higher Eastern Cooperative Oncology Group (ECOG) performance status (PS) (P<0.001), increased metastatic site involvement (P<0.001), advanced stage disease (P<0.001), with liver metastasis (P=0.008) and/or bone metastasis (P<0.001) at baseline. Cumulative incidence of CNS failure in years 1, 2 and 3 was 10.1%, 21.5% and 30.0%, respectively. In multivariate analysis, cumulative incidence was significantly higher in patients with ECOG PS ≥2 (P<0.001), uncommon EGFR mutations (P=0.001), and no baseline pleural metastasis (P=0.017). Median TOT was 16.0 months (95% CI: 14.8-17.2) and, in patients with CNS failure, without CNS failure, and with baseline BM was 12.2, 18.9, and 14.1 months, respectively (P<0.001). Median OS was 52.9 months (95% CI: 45.4-60.3) and, in patients with CNS failure, without CNS failure, and with baseline BM was 29.1, 67.3 and 48.5 months, respectively (P<0.001).First-line afatinib in the real-world setting showed clinically meaningful effectiveness in patients with EGFR-mutant NSCLC and BM. CNS failure was a poor prognostic factor for TOT and OS correlating with younger age, poor ECOG PS, higher metastatic number, advanced disease stage, uncommon EGFR mutations, and baseline liver and/or bone metastases." @default.
• W4382399821 created "2023-06-29" @default.
• W4382399821 creator A5006227181 @default.
• W4382399821 creator A5013806664 @default.
• W4382399821 creator A5014976482 @default.
• W4382399821 creator A5021055879 @default.
• W4382399821 creator A5021370060 @default.
• W4382399821 creator A5024831387 @default.
• W4382399821 creator A5026187512 @default.
• W4382399821 creator A5026518670 @default.
• W4382399821 creator A5036157714 @default.
• W4382399821 creator A5061814504 @default.
• W4382399821 creator A5064663707 @default.
• W4382399821 creator A5066767378 @default.
• W4382399821 creator A5070077415 @default.
• W4382399821 creator A5071284791 @default.
• W4382399821 creator A5076637904 @default.
• W4382399821 creator A5081114498 @default.
• W4382399821 creator A5082152803 @default.
• W4382399821 date "2023-06-01" @default.
• W4382399821 modified "2023-09-26" @default.
• W4382399821 title "Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors" @default.
• W4382399821 cites W1584673858 @default.
• W4382399821 cites W1980497534 @default.
• W4382399821 cites W1984269605 @default.
• W4382399821 cites W2019607817 @default.
• W4382399821 cites W2036423966 @default.
• W4382399821 cites W2039202448 @default.
• W4382399821 cites W2040299716 @default.
• W4382399821 cites W2041835001 @default.
• W4382399821 cites W2078803344 @default.
• W4382399821 cites W2096198395 @default.
• W4382399821 cites W2107869150 @default.
• W4382399821 cites W2123753884 @default.
• W4382399821 cites W2134640949 @default.
• W4382399821 cites W2138089710 @default.
• W4382399821 cites W2147840374 @default.
• W4382399821 cites W2155073814 @default.
• W4382399821 cites W2155894313 @default.
• W4382399821 cites W2159013299 @default.
• W4382399821 cites W2164207083 @default.
• W4382399821 cites W2171139285 @default.
• W4382399821 cites W2268267848 @default.
• W4382399821 cites W2339311613 @default.
• W4382399821 cites W2494292000 @default.
• W4382399821 cites W2513965327 @default.
• W4382399821 cites W2552721612 @default.
• W4382399821 cites W2587420003 @default.
• W4382399821 cites W2612786119 @default.
• W4382399821 cites W2744886365 @default.
• W4382399821 cites W2768661930 @default.
• W4382399821 cites W2770828094 @default.
• W4382399821 cites W2783694051 @default.
• W4382399821 cites W2789821514 @default.
• W4382399821 cites W2792821195 @default.
• W4382399821 cites W2806325305 @default.
• W4382399821 cites W2808643725 @default.
• W4382399821 cites W2893850807 @default.
• W4382399821 cites W2900029764 @default.
• W4382399821 cites W2903122310 @default.
• W4382399821 cites W2916893580 @default.
• W4382399821 cites W2917596286 @default.
• W4382399821 cites W2926167018 @default.
• W4382399821 cites W2938495237 @default.
• W4382399821 cites W2964623804 @default.
• W4382399821 cites W3046060970 @default.
• W4382399821 cites W3085153121 @default.
• W4382399821 cites W3086164260 @default.
• W4382399821 cites W3091781059 @default.
• W4382399821 cites W3111257261 @default.
• W4382399821 cites W3111340659 @default.
• W4382399821 cites W3128646645 @default.
• W4382399821 cites W3132662371 @default.
• W4382399821 cites W3133163719 @default.
• W4382399821 cites W3134633575 @default.
• W4382399821 cites W3137719687 @default.
• W4382399821 cites W3159793715 @default.
• W4382399821 cites W3164232989 @default.
• W4382399821 cites W3178766866 @default.
• W4382399821 cites W3181790708 @default.
• W4382399821 cites W3200767196 @default.
• W4382399821 cites W4200397469 @default.
• W4382399821 cites W4205246856 @default.
• W4382399821 cites W4312220210 @default.
• W4382399821 doi "https://doi.org/10.21037/tlcr-22-832" @default.
• W4382399821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37425421" @default.
• W4382399821 hasPublicationYear "2023" @default.
• W4382399821 type Work @default.
• W4382399821 citedByCount "0" @default.
• W4382399821 crossrefType "journal-article" @default.
• W4382399821 hasAuthorship W4382399821A5006227181 @default.
• W4382399821 hasAuthorship W4382399821A5013806664 @default.
• W4382399821 hasAuthorship W4382399821A5014976482 @default.
• W4382399821 hasAuthorship W4382399821A5021055879 @default.
• W4382399821 hasAuthorship W4382399821A5021370060 @default.
• W4382399821 hasAuthorship W4382399821A5024831387 @default.
• W4382399821 hasAuthorship W4382399821A5026187512 @default.
• W4382399821 hasAuthorship W4382399821A5026518670 @default.

• next